Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Amgen Astellas BioPharma to Become Amgen’s Wholly Owned Subsidiary; Continue Copromotion with Astellas
January 24, 2020
- Takeda to Liquidate Shire’s Irish Holding Firm
January 23, 2020
- Kissei’s Spinocerebellar Degeneration Drug Fails to Meet Primary Goal in PIII, but Shows Positive Results in Severe Patients
January 23, 2020
- Otsuka Ties Up with UK’s PhoreMost, Initial Focus on Gene Therapy
January 22, 2020
- Towa to Develop Adherence Support Tools with Game Maker, Eyes Launch in FY2021
January 22, 2020
- Pfizer Rolls Out Japan’s Second Rituxan Biosimilar
January 21, 2020
- GSK, NCC Join Hands to Propel Cancer Drug Development, Translational Research
January 21, 2020
- Keytruda Snags Best-Seller Title in 2019 Drug Ranking: Encise
January 20, 2020
- Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist
January 20, 2020
- Forxiga Filed for Chronic Heart Failure in Japan: AstraZeneca
January 20, 2020
- Nichi-Iko Quits Herceptin Biosimilar, Focus Now on Avastin Follow-On
January 20, 2020
- Mitsubishi Tanabe to Be Delisted from TSE on February 27
January 20, 2020
- Astellas to Build New API Facility for Prograf in Toyama
January 20, 2020
- Astellas Completes US$3 Billion Audentes Buyout
January 17, 2020
- Asahi Kasei Closes Veloxis Acquisition
January 16, 2020
- JT Grabs Japan Rights to Dermavant’s Psoriasis/Eczema Drug
January 16, 2020
- Orix to Acquire Majority Stake in Generic Drug Maker Kobayashi Kako
January 16, 2020
- ASKA Bags Japan Rights for Cervical Dysplasia Therapy from Kyoto Univ. Spinoff
January 16, 2020
- Tapped as Next Mitsubishi Tanabe Chief, Hiroaki Ueno Vows to Enrich Pipeline, Accelerate Global Biz
January 15, 2020
- Astellas, Adaptimmune Hook Up on Off-the-Shelf Cell Therapies
January 15, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…